Clinical trials: Lipids Metabolism
Non-alcoholic Steatohepatitis, Hypertriglyceridemia
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
This is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in non-alcoholic steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) subjects…
- Conditions
- Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
- Trial name
- NCT02681055
- Testing
- MN-001
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Fabry Disease
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients
The objective of this treatment protocol is to provide guidance to Treating Physicians who seek access to pegunigalsidase alfa for Fabry patients whose clinical condition, in the opinion of the Treating Physician, requires…
- Trial name
- NCT04552691
- Testing
- Pegunigalsidase Alfa
- Where
- 11 sites in United States
- Sponsor
- Chiesi Farmaceutici S.p.A.
Dercum's Disease
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas
This Phase 2 study will be an open-label and randomized study to assess the efficacy and safety of CBL-514 in participants with Dercum's Disease lipomas.
- Trial name
- NCT05387733
- Testing
- 10 mg CBL-514 per injection, 15 mg CBL-514 per injection
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Hypercholesterolemia
Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile
Background: In recent years, probiotics have shown promise in treating a variety of diseases. Previously, the investigators have reported on the clinical efficacy of bile salt hydrolase active Lactobacillus reuteri NCIMB 30242 in…
- Trial name
- NCT02216825
- Testing
- Delayed release capsule, L. reuteri NCIMB 30242, escalated dose, Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose
- Volunteers
- 10 people
- Sponsor
- Micropharma Limited
Impaired Fasting Glucose
The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population
The primary aim of this study is to evaluate the effect of a fibre rich health food drink on the post prandial glucose and triglyceride peak in healthy overweight adults with impaired fasting glucose (IFG).
- Trial name
- NCT02119325
- Testing
- 25% fibre, 0% fibre
- Where
- India
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dyslipidemias, Cardiovascular Risk Factor
Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
Clinical Trial Phase III, experimental, simple blind, randomized with two treatment groups, multicentric, longitudinal, to evaluate the therapuetic efficacy to dislipydemias in mexican adult population.
- Trial name
- NCT03696940
- Testing
- L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg, Atorvastatin 10mg
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Laboratorios Grossman, S.A.
Fabry Disease
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
Fabry Disease (FD) is a rare X-linked lysosomal storage disorder (LSD) caused by mutations in the GLA gene which translates into decreased activity or lack of function of the enzyme alpha-galactosidase A (α-GAL A) and…
- Trial name
- NCT03228940
- Testing
- RVX000222
- Where
- Canada
- Sponsor
- Resverlogix Corp
Hypercholesterolemia
Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study
Primary Objective: To estimate the overall combined rate of major structural birth defects in infants of mothers with atherosclerotic cardiovascular disease (ASCVD) and/or familial hypercholesterolemia (FH) exposed to Praluent®…
- Trial name
- NCT03379558
- Testing
- ALIROCUMAB SAR236553 (REGN727)
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Gaucher Disease
Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease
Gaucher disease is an inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCB) that leads to progressive accumulation of glucocerebroside within macrophages and subsequent tissue and organ damage; typically of the…
- Trial name
- NCT01614574
- Testing
- velaglucerase alfa
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Shire
Dyslipidemias, Coronary Heart Disease
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal…
- Conditions
- Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
- Trial name
- NCT00639158
- Testing
- ABT-335, atorvastatin, ezetimibe
- Where
- 118 sites in United States
- Volunteers
- 543 people
- Sponsor
- Abbott
Dyslipidemias
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
The purpose of the study is to evaluate the effectiveness of atorvastatin in lowering cholesterol and getting these high risk patients to their goals of LDL <115 mg/dl across starting doses of 10 mg, 20 mg, or 40 mg with one step…
- Trial name
- NCT00644670
- Testing
- Atorvastatin
- Where
- 17 sites in Belgium
- Volunteers
- 232 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dyslipidemias
PocDoc Lipids Out-of-Surgery Study
This study seeks to improve access to lipid testing in out-of-surgery locations using PocDoc, a UKCA approved IVD device that measures a full 5 marker lipid panel using a smartphone or tablet.
- Trial name
- NCT06258005
- Testing
- PocDoc
- Where
- United Kingdom
- Volunteers
- 4,256 people, healthy volunteers welcome
- Sponsor
- Vital Signs Solutions Ltd
Cardiovascular Diseases, Hyperlipidemias
Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control
Fimasartan and Rosuvastatin for hypertension and dyslipidemia control
- Trial name
- FIMARO (NCT02913794)
- Where
- South Korea
- Volunteers
- 541 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Homozygous Familial Hypercholesterolemia
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).
- Trial name
- TESLA (NCT01588496)
- Testing
- Evolocumab
- Where
- 21 sites in United States, Belgium and 10 more
- Volunteers
- 58 people
- Sponsor
- Amgen
Hypertension, Hypercholesterolemia
A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin
To assess the changes in the trough Systolic Blood Pressure (SBP) and the percent changes in Low Density Lipoprotein-Cholesterol (LDL-C) from baseline at Week 8 in the treatment period
- Trial name
- NCT00530946
- Testing
- Amlodipine 2.5mg/Atorvastatin 5mg, Amlodipine 2.5mg/Atorvastatin 10mg, Amlodipine 5mg/Atorvastatin 5mg
- Where
- 17 sites in Japan
- Volunteers
- 165 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Severe Hypertriglyceridemia, Mixed Dyslipidaemia
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)
- Trial name
- INDIGO-1 (NCT02944383)
- Testing
- Gemcabene
- Where
- 49 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)
A phase I clinical trial to evaluate the tolerability and the pharmacokinetics of CKD-348(5).
- Trial name
- NCT05749861
- Testing
- CKD-348(5), CKD-828, D097, D337
- Where
- South Korea
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
HIV Infections, Lipodystrophy
TH9507 in Patients With HIV-Associated Lipodystrophy
HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in…
- Trial name
- NCT00123253
- Testing
- TH9507
- Where
- 42 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Theratechnologies
Dyslipidemia
A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)
A study to evaluate the inter- and intra subject variabilities of flow-mediated dilation (FMD) of brachial artery and nitroglycerin (GTN) induced dilation of brachial artery.
- Trial name
- NCT01104519
- Testing
- Niaspan
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Combined Hyperlipidemia
A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia
This is a multi-center, double blind, prospective, longitudinal, randomized, 12-week study with a 52-week open-label follow-up to evaluate the safety and efficacy of daily administration of Pravastatin 40 mg or Fenofibrate 160 mg…
- Trial name
- NCT00459745
- Testing
- Pravafen, Pravastatin, Fenofibrate
- Where
- 57 sites in United States
- Volunteers
- 481 people
- Sponsor
- Shionogi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.